UK Markets close in 1 hr 56 mins
  • FTSE 100

    5,574.36
    -7.39 (-0.13%)
     
  • FTSE 250

    17,187.60
    +9.92 (+0.06%)
     
  • AIM

    949.49
    +0.19 (+0.02%)
     
  • GBP/EUR

    1.1089
    +0.0026 (+0.23%)
     
  • GBP/USD

    1.2954
    +0.0031 (+0.2384%)
     
  • BTC-GBP

    10,265.45
    -18.89 (-0.18%)
     
  • CMC Crypto 200

    260.08
    -3.55 (-1.35%)
     
  • S&P 500

    3,259.36
    -50.75 (-1.53%)
     
  • DOW

    26,310.73
    -348.38 (-1.31%)
     
  • CRUDE OIL

    35.41
    -0.76 (-2.10%)
     
  • GOLD FUTURES

    1,883.90
    +15.90 (+0.85%)
     
  • NIKKEI 225

    22,977.13
    -354.81 (-1.52%)
     
  • HANG SENG

    24,107.42
    -479.18 (-1.95%)
     
  • DAX

    11,566.76
    -31.31 (-0.27%)
     
  • CAC 40

    4,586.04
    +16.37 (+0.36%)
     

Global Psychedelic Therapeutics Market Report 2020: Regulation, Toxicity Concerns, Procurement-Related Challenges and Perceptions Regarding Medical Use

Research and Markets
·6-min read

Dublin, Oct. 14, 2020 (GLOBE NEWSWIRE) -- The "Global Psychedelic Therapeutics Market by Type of Psychedelic Substance, by Origin, by Type of Therapy, by Route of Administration and by Key Geographies: Industry Trends and Global Forecasts, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

"Global Psychedelic Therapeutics Market, 2020-2030" report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of psychedelic therapeutics, over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain.

Early in the 21st Century, XYREM, a gamma-hydroxybutyric acid based psychedelic drug was approved for the treatment of cataplexy in patients suffering from narcolepsy. In 2019, SPRAVATO (an analogue of ketamine), developed by Johnson and Johnson, was approved for use in patients suffering from treatment-resistant depression.

Recently, the US FDA granted the breakthrough drug designation to 3,4-Methylenedioxymethamphetamine (MDMA) and psilocybin, based on clinical evidence of these substances being capable of offering substantial therapeutic benefit in treating major depressive disorder, post-traumatic stress disorder and treatment resistant depression over other available therapies.

Currently, several stakeholders in the pharmaceutical industry are actively evaluating the therapeutic potential of psychedelic substances against a wide array of mental health problems. As more players achieve proof-of-concept, this niche market is anticipated to witness substantial growth in the mid-long term.

Key Questions Answered

  • Who are the leading industry players in this domain?

  • What are the key clinical conditions addressed by psychedelic therapeutics?

  • Who are the key opinion leaders from renowned academic and research institutes who can help you drive your development efforts?

  • What are the factors that are likely to influence the evolution of this market?

  • Which partnership models are commonly adopted by stakeholders in this industry?

  • Which are the most active clinical trial centres in this domain?

  • How is the current and future market opportunity likely to be distributed across key market segments?

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. History of Psychedelic Substance
3.3. Potential Therapeutic Application of Psychedelic Substance
3.4. Regulation, Toxicity Concerns, Procurement-Related Challenges and Perceptions Regarding Medical Use
3.5. Future Opportunity

4. MARKET LANDSCAPE: PSYCHEDELIC THERAPEUTICS
4.1. Chapter Overview
4.2. Psychedelic Therapeutics: Marketed and Development Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Type of Psychedelic Substance
4.2.3. Analysis by Origin of Psychedelic Substance
4.2.4. Analysis by Target Therapeutic Area
4.2.5. Analysis by Type of Therapy
4.2.6. Analysis by Route of Administration
4.2.7. Analysis by Dosing Frequency
4.3. Psychedelic Therapeutics: List of Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4. 3.3. Analysis by Location of Headquarters
4.4. Grid Analysis: Distribution by Phase of Development, Origin of Psychedelic Substance and Location of Headquarters

5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Celon Pharma
5.3. iX Biopharma
5.4. MAPS Public Benefit
5.5. MindMed
5.6. Janssen Pharmaceuticals
5.7. Jazz Pharmaceutical

6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. Psychedelic Therapeutics: Clinical Trial Analysis
6.3.1. Analysis by Trial Registration Year
6.3.2. Analysis by Trial Phase
6.3.3. Analysis by Trial Recruitment Status
6.3.4. Analysis by Trial Registration Year and Number of Patients Enrolled
6.3.5. Analysis by Study Design
6.3.6. Leading Trial Sponsors: Analysis by Number of Registered Trials
6.3.7. Leading Players: Analysis by Number of Registered Trials
6.3.8. Analysis by Trial Focus
6.3.9. Analysis by Target Therapeutic Area
6.3.10. Popular Psychedelic Substance: Analysis by Number of Registered Trials
6.3.11. Geographical Analysis by Number of Registered Trials
6.3.12. Geographical Analysis by Number of Patients Enrolled

7. CLINICAL TRIAL SITE ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Psychedelic Therapeutics: Clinical Trial Site Analysis
7.3.1. Analysis by Geographical Location

8. KEY OPINION LEADER (KOL) ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Methodology
8.3. Principal Investigators Involved in Clinical Trials
8.3.1. Analysis by Type of Organization (KOL Affiliation)
8.3.2. Geographical Distribution of KOLs
8.4. Prominent KOLs
8.5. KOL Benchmarking: Assessment versus Third Party (ResearchGate Score)
8.6. Most Active KOLs
8.6.1. KOL Profile: A (Emory School of Medicine)
8.6.2. KOL Profile: B (Imperial College London)
8.6.3. KOL Profile: C (Rigshospitalet)
8.6.4. KOL Profile: D (Thriving Mind South Florida)
8.6.5. KOL Profile: E (University Health Network)

9. ACADEMIC GRANTS ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Psychedelic Therapeutics: Analysis of Academic Grants

10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Psychedelic Therapeutics: List of Partnerships and Collaborations

11. MERGERS AND ACQUISITIONS
11.1. Chapter Overview
11.2. Acquisition Models
11.3. Psychedelic Therapeutics: Mergers and Acquisitions

12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Global Psychedelic Therapeutics Market, 2020-2030
12.4. Global Psychedelic Therapeutics Market: Individual Product Sales Forecasts
12.4.1. Xyrem (Jazz Pharmaceutical)
12.4.2. Spravato (Janssen Pharmaceuticals)
12.4.3. JPZ-258 (Janssen Pharmaceuticals)
12.4.4. FT218 (Avadel Pharmaceuticals)
12.4.5. Unnamed MDMA (MAPS Public Benefit)
12.4.6. COMP360 (COMPASS Pathways)
12.4.7. Unnamed Psilocybin (The Emmes Company)
12.4.8. Esketamine DPI (Celon Pharma)
12.4.9. Wafermine (iX Biopharma)
12.5. Global Psychedelic Therapeutics Market: Distribution by Origin of Psychedelic Substance, 2020-2030
12.6. Global Psychedelic Therapeutics Market: Distribution by Type of Psychedelic Substance, 2025-2030
12.7. Global Psychedelic Therapeutics Market: Distribution by Geography, 2020-2030
12.8. Global Psychedelic Therapeutics Market: Distribution by Target Therapeutic Area, 2020-2030
12.9. Global Psychedelic Therapeutics Market: Distribution by Route of Administration, 2020-2030

13. CONCLUDING REMARKS
13.1. Chapter Overview
13.2. Key Takeaways

14. EXECUTIVE INSIGHTS
14.1. Chapter Overview
14.2 CaaMTech
14.3. MindMed
14.4. iX Biopharma
14.5 Orthogonal Thinkers
14.6 COMPASS Pathways
14.7 Yale University

For more information about this report visit https://www.researchandmarkets.com/r/1as09c

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900